Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.34 |
| ▸ | MAOA | P21397 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22867975 | 0.92 | METAP2 (0.45) | METAP2METAP1OPRD1OPRM1OPRK1 | |
| SCHEMBL22868100 | 0.91 | METAP2 (0.47) | METAP2METAP1CHRNA7KEAP1NFE2L2 | |
| SCHEMBL20289744 | 0.81 | TSHR (0.41) | SLC6A4TDP1 | |
| SCHEMBL6542877 | 0.80 | SLC6A2 (0.39) | SLC6A4 | |
| SCHEMBL5453640 | 0.80 | DPP4 (0.40) | OPRD1OPRM1OPRK1OPRL1MAOA | |
| SCHEMBL5455820 | 0.80 | SLC6A2 (0.39) | SLC6A4 | |
| SCHEMBL5463403 | 0.80 | SLC6A4 (0.44) | OPRD1OPRM1OPRK1OPRL1SLC6A4 | |
| SCHEMBL3061093 | 0.79 | SCN4A (0.44) | — | |
| SCHEMBL5455701 | 0.79 | SCN4A (0.44) | — | |
| SCHEMBL6854233 | 0.79 | SCN4A (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420679-B2 | Aminothiazole derivatives and their use as CRF receptor ligands | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20070281919-A1 | Aminothiazole Derivatives And Their Use As CRF Receptor Ligands | SANOFI-AVENTIS (FR) | 2007-12-06 | — | — | US | disclosed |
| US-6806282-B2 | HAVE AN ANTAGONISTIC ACTIVITY WITH RESPECT TO CORTICOTROPIN RELEASING FACTOR | SANOFI-SYNTHELABO (FR) | 2004-10-19 | — | — | US | disclosed |
| EP-1200419-B1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI SYNTHELABO (FR) | 2004-04-14 | — | — | EP | disclosed |
| US-20030162771-A1 | Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h-[1,2,4] triazol, methods for producing them and pharmaceutical compositions containing them | SANOFI (FR) | 2003-08-28 | — | — | US | disclosed |
| US-6586456-B1 | Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide | SANOFI-SYNTHELABO (FR) | 2003-07-01 | — | — | US | disclosed |
| EP-1242389-A2 | NOVEL BRANCHED SUBSTITUTED AMINO DERIVATIVES OF 3-AMINO-1-PHENYL-1H[1,2,4]TRIAZOL, METHODS FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2002-09-25 | — | — | EP | disclosed |
| EP-1200419-A1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI-SYNTHELABO (FR) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001044207-A2 | NOVEL BRANCHED SUBSTITUTED AMINO DERIVATIVES OF 3-AMINO-1-PHENYL-1H[1,2,4]TRIAZOL, METHODS FOR PRODUCING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001005776-A1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI-SYNTHELABO (FR) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281919-A1 | Aminothiazole Derivatives And Their Use As CRF Receptor Ligands | CRH, CRHR1, CRHR2 | METAP2 751/4885METAP1 585/4885OPRD1 186/4885 |
| US-20030162771-A1 | Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h-[1,2,4] triazol, methods for producing them and pharmaceutical compositions containing them | CRHR1, ADRA2C, NPY1R | METAP2 2773/4885METAP1 1655/4885OPRD1 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.